Capital World Investors Has $1.42 Billion Holdings in Ionis Pharmaceuticals, Inc. $IONS

Capital World Investors raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 41.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,961,299 shares of the company’s stock after purchasing an additional 5,238,571 shares during the quarter. Capital World Investors owned 0.11% of Ionis Pharmaceuticals worth $1,420,918,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jain Global LLC raised its stake in shares of Ionis Pharmaceuticals by 3,037.4% in the 3rd quarter. Jain Global LLC now owns 225,739 shares of the company’s stock valued at $14,768,000 after purchasing an additional 218,544 shares during the period. DAVENPORT & Co LLC raised its stake in shares of Ionis Pharmaceuticals by 248.3% in the 4th quarter. DAVENPORT & Co LLC now owns 217,897 shares of the company’s stock valued at $17,238,000 after purchasing an additional 155,334 shares during the period. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Ionis Pharmaceuticals by 161.3% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 155,790 shares of the company’s stock valued at $10,192,000 after purchasing an additional 96,164 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Ionis Pharmaceuticals by 230.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 878,155 shares of the company’s stock valued at $57,449,000 after purchasing an additional 612,362 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Ionis Pharmaceuticals by 548.7% in the 4th quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock valued at $2,643,000 after purchasing an additional 28,259 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, EVP Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.85, for a total transaction of $2,827,460.45. Following the completion of the transaction, the executive vice president owned 11,714 shares in the company, valued at approximately $888,506.90. This trade represents a 76.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Elizabeth L. Hougen sold 215,048 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $72.40, for a total value of $15,569,475.20. Following the transaction, the executive vice president owned 92,832 shares of the company’s stock, valued at $6,721,036.80. The trade was a 69.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 327,480 shares of company stock valued at $24,030,004 in the last three months. Corporate insiders own 1.81% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $74.48 on Monday. The stock has a market capitalization of $12.31 billion, a price-to-earnings ratio of -35.98 and a beta of 0.37. The business has a 50-day moving average of $74.95 and a 200-day moving average of $77.82. The company has a debt-to-equity ratio of 2.75, a current ratio of 4.10 and a quick ratio of 4.09. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $34.78 and a fifty-two week high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The business had revenue of $246.09 million during the quarter, compared to analysts’ expectations of $195.57 million. During the same quarter last year, the company posted ($0.93) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 86.4% on a year-over-year basis. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IONS has been the topic of several recent research reports. Raymond James Financial initiated coverage on Ionis Pharmaceuticals in a research note on Friday, April 10th. They issued an “outperform” rating and a $104.00 price target on the stock. Bank of America raised their price objective on Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Oppenheimer restated an “outperform” rating and issued a $111.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, April 30th. Stifel Nicolaus raised their price objective on Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a “hold” rating in a report on Thursday, February 26th. Finally, Canaccord Genuity Group started coverage on Ionis Pharmaceuticals in a report on Monday, April 20th. They issued a “buy” rating and a $110.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $100.90.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.